Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Open Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of XER-001 (Amifostibe for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment of Locally-Advanced Pancreatic Adenocarcinoma

NCT07157033 is registered in ClinicalTrials.gov with Xerient Pharma as lead sponsor.

NCT NCT07157033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07157033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Open Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of XER-001 (Amifostibe for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment of Locally-Advanced Pancreatic Adenocarcinoma
Lead sponsor
Xerient Pharma
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 1, 2026
Completion date
July 31, 2034
Enrollment
36 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreas cancer, locally advanced pancreatic adenocarcinoma, locally advanced pancreatic ductal adenocarcinoma